Q2 EPS Forecast for Elevance Health Reduced by Analyst

Elevance Health, Inc. (NYSE:ELV) – Research analysts at Zacks Research cut their Q2 2025 earnings estimates for shares of Elevance Health in a note issued to investors on Monday, May 5th. Zacks Research analyst K. Dey now expects that the company will earn $9.36 per share for the quarter, down from their prior estimate of $9.85. The consensus estimate for Elevance Health’s current full-year earnings is $33.96 per share. Zacks Research also issued estimates for Elevance Health’s Q3 2025 earnings at $8.37 EPS, FY2026 earnings at $38.78 EPS and Q1 2027 earnings at $13.31 EPS.

Elevance Health (NYSE:ELV) last announced its earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.60 by $1.37. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. The firm had revenue of $48.77 billion during the quarter, compared to analyst estimates of $46.26 billion.

ELV has been the topic of a number of other reports. Sanford C. Bernstein reissued an “outperform” rating on shares of Elevance Health in a report on Friday, March 28th. Barclays upped their price target on shares of Elevance Health from $512.00 to $522.00 and gave the stock an “overweight” rating in a report on Wednesday, April 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $478.00 price objective on shares of Elevance Health in a research note on Wednesday, April 23rd. Robert W. Baird reaffirmed a “neutral” rating and issued a $529.00 price target (down previously from $625.00) on shares of Elevance Health in a report on Tuesday, April 15th. Finally, Mizuho upped their price objective on shares of Elevance Health from $455.00 to $505.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 9th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $510.38.

Elevance Health Trading Down 1.1 %

Shares of ELV stock opened at $413.01 on Wednesday. The stock has a market capitalization of $93.31 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 1.18 and a beta of 0.66. Elevance Health has a 1 year low of $362.21 and a 1 year high of $567.26. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The company’s fifty day simple moving average is $424.00 and its two-hundred day simple moving average is $404.69.

Institutional Investors Weigh In On Elevance Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Accredited Wealth Management LLC purchased a new stake in Elevance Health in the 4th quarter valued at about $25,000. Flagship Wealth Advisors LLC purchased a new stake in Elevance Health during the 4th quarter worth approximately $26,000. Private Wealth Management Group LLC increased its position in shares of Elevance Health by 152.0% in the 1st quarter. Private Wealth Management Group LLC now owns 63 shares of the company’s stock valued at $27,000 after acquiring an additional 38 shares during the period. OFI Invest Asset Management purchased a new stake in Elevance Health during the 4th quarter valued at about $29,000. Finally, WealthTrak Capital Management LLC acquired a new stake in shares of Elevance Health during the fourth quarter worth about $29,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the completion of the transaction, the executive vice president now directly owns 10,116 shares in the company, valued at approximately $4,008,970.80. The trade was a 25.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Mark Kaye sold 4,588 shares of the firm’s stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $424.82, for a total value of $1,949,074.16. Following the sale, the chief financial officer now directly owns 18,977 shares in the company, valued at approximately $8,061,809.14. This represents a 19.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,535 shares of company stock valued at $3,521,612. 0.29% of the stock is owned by insiders.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th will be issued a $1.71 dividend. The ex-dividend date of this dividend is Tuesday, June 10th. This represents a $6.84 annualized dividend and a yield of 1.66%. Elevance Health’s payout ratio is 26.69%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.